Efficacy and Safety of Shengxuening Tablets in the Treatment of Cancer-related Anemia ：A Meta-analysis
- VernacularTitle:生血宁片治疗肿瘤相关性贫血有效性和安全性的Meta分析
- Author:
Chunlu LI
1
;
Feihong HUANG
2
;
Yun YE
3
;
Jianming WU
3
;
Wenjun ZOU
1
Author Information
1. School of Pharmacy，Chengdu University of TCM，Chengdu 611130，China
2. School of Pharmacy，Southwest Medical University，Sichuan Luzhou 646000，China
3. School of Pharmacy，Southwest Medical University，Sichuan Luzhou 646000，China;Dept. of Pharmacy，the Affiliated Hospital of Southwest Medical University，Sichuan Luzhou 646000，China
- Publication Type:Journal Article
- Keywords:
Shengxuening tablets;
Cancer-related anemia;
Meta-analysis;
Efficacy;
Safety
- From:
China Pharmacy
2020;31(12):1494-1494
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE：To systematically evaluate efficacy and safety of Shengxuening tablets in the treatment of cancer-related anemia （CRA），and to provide evidence-based reference for clinical drug use. METHODS ：Retrieved from the Cochrane Library ，PubMed，Embase，CJFD，CSJD，Wanfang database and CBM ，RCTs about Shengxuening tablets alone or combined with routine therapy （trial group ）versus routine therapy or blank control （control group ）in the treatment of CRA were collected from inception to July 2019. After literature screening and data extraction ，quality evaluation of included literatures with system evaluation bias risk evaluation tool provided by Cochrane intervention measure system evaluation manual 3.0.2， Meta-analysis of the included literatures was carried out by using Rev Man 5.3 software. RESULTS ：A total of 9 RCTs involving 681 patients were included. Results of Meta-analysis showed that red blood cell count [MD ＝0.62，95％CI（0.30，0.93），P＝0.000 1]， hematocrit level [MD ＝6.12，95％CI（4.97，7.27），P＜0.000 01]，hemoglobin level [MD ＝7.47，95％CI（5.29，9.66），P＜0.000 01]， white blood cell count [MD ＝0.31，95％CI（0.12，0.50），P＝0.001]，platelet count [MD ＝3.06，95％CI（0.84，5.28），P＝0.007]， KPS score [MD ＝5.15，95％CI（2.79，7.51），P＜0.000 1]，quality of life score [MD ＝28.27，95％CI（19.27，37.28），P＜0.000 01] after treatment in trial group were significantly higher than control group ，while the incidence of ADR [RR ＝0.14，95％CI（0.03， 0.76），P＝0.02] in trial group was significantly lower than control group. CONCLUSIONS ：Shengxuening tablets have good efficacy and safety in the treatment of CRA.
